Alison N Kurimchak (Alison Kurimchak, Alison M Kurimchak)

Publication Activity (10 Years)

Years Active: 2020-2024
Publications (10 Years): 19

Top Topics

Dna Damage Response

Top Venues

Nature communications

Research square

Science signaling

This page only lists publications with an associated author ORCID identifier.

Publications

Jonathan Chernoff, Konstantin Budagyan, Alexa Cannon, Adam Chatoff, Nathaniel W Snyder, Alison N Kurimchak, James Duncan
KRAS mutation-selective requirement for ACSS2 in colorectal adenoma formation. Research square (2024)
Alexa C Cannon, Konstantin Budagyan, Cristina Uribe-Alvarez, Alison N Kurimchak, Daniela Araiza-Olivera, Kathy Q Cai, Suraj Peri, Yan Zhou, James S Duncan, Jonathan Chernoff
Unique vulnerability of RAC1-mutant melanoma to combined inhibition of CDK9 and immune checkpoints. Oncogene 43 (10) (2024)
Jason S Wasserman, Bulat Faezov, Kishan R Patel, Alison N Kurimchak, Seren M Palacio, David J Glass, Holly Fowle, Brennan C McEwan, Qifang Xu, Ziran Zhao, Lauren E Cressey, Neil Johnson, James S Duncan, Arminja N Kettenbach, Roland L Dunbrack, Xavier Graña
FAM122A ensures cell cycle interphase progression and checkpoint control by inhibiting B55α/PP2A through helical motifs. Nature communications 15 (1) (2024)
Alexa C Cannon, Konstantin Budagyan, Cristina Uribe-Alvarez, Alison N Kurimchak, Daniela Araiza-Olivera, Kathy Q Cai, Suraj Peri, Yan Zhou, James S Duncan, Jonathan Chernoff
Unique vulnerability of RAC1-mutant melanoma to combined inhibition of CDK9 and immune checkpoints. Oncogene 43 (10) (2024)
Alexa C Cannon, Konstantin Budagyan, Cristina Uribe-Alvarez, Alison N Kurimchak, Daniela Araiza-Olivera, Kathy Q Cai, Suraj Peri, Yan Zhou, James S Duncan, Jonathan Chernoff
Unique vulnerability of RAC1-mutant melanoma to combined inhibition of CDK9 and immune checkpoints. Oncogene (2024)
Jonathan Chernoff, Konstantin Budagyan, Alexa Cannon, Adam Chatoff, Nathaniel W Snyder, Alison N Kurimchak, James Duncan
KRAS mutation-selective requirement for ACSS2 in colorectal adenoma formation. Research square (2024)
Jason S Wasserman, Bulat Faezov, Kishan R Patel, Alison N Kurimchak, Seren M Palacio, David J Glass, Holly Fowle, Brennan C McEwan, Qifang Xu, Ziran Zhao, Lauren E Cressey, Neil Johnson, James S Duncan, Arminja N Kettenbach, Roland L Dunbrack, Xavier Graña
FAM122A ensures cell cycle interphase progression and checkpoint control by inhibiting B55α/PP2A through helical motifs. Nature communications 15 (1) (2024)
Jason S Wasserman, Bulat Faezov, Kishan R Patel, Alison N Kurimchak, Seren M Palacio, David J Glass, Holly Fowle, Brennan C McEwan, Qifang Xu, Ziran Zhao, Lauren E Cressey, Neil Johnson, James S Duncan, Arminja N Kettenbach, Roland L Dunbrack, Xavier Graña
FAM122A ensures cell cycle interphase progression and checkpoint control by inhibiting B55α/PP2A through helical motifs. Nature communications 15 (1) (2024)
Alexa C Cannon, Konstantin Budagyan, Cristina Uribe-Alvarez, Alison N Kurimchak, Daniela Araiza-Olivera, Kathy Q Cai, Suraj Peri, Yan Zhou, James S Duncan, Jonathan Chernoff
Unique vulnerability of RAC1-mutant melanoma to combined inhibition of CDK9 and immune checkpoints. Oncogene (2024)
Alexa C Cannon, Konstantin Budagyan, Cristina Uribe-Alvarez, Alison N Kurimchak, Daniela Araiza-Olivera, Kathy Q Cai, Suraj Peri, Yan Zhou, James S Duncan, Jonathan Chernoff
Unique vulnerability of RAC1-mutant melanoma to combined inhibition of CDK9 and immune checkpoints. Oncogene 43 (10) (2024)
Jason S Wasserman, Bulat Faezov, Kishan R Patel, Alison N Kurimchak, Seren M Palacio, David J Glass, Holly Fowle, Brennan C McEwan, Qifang Xu, Ziran Zhao, Lauren E Cressey, Neil Johnson, James S Duncan, Arminja N Kettenbach, Roland L Dunbrack, Xavier Graña
FAM122A ensures cell cycle interphase progression and checkpoint control by inhibiting B55α/PP2A through helical motifs. Nature communications 15 (1) (2024)
Jason S Wasserman, Bulat Faezov, Kishan R Patel, Alison N Kurimchak, Seren M Palacio, David J Glass, Holly Fowle, Brennan C McEwan, Qifang Xu, Ziran Zhao, Lauren E Cressey, Neil Johnson, James S Duncan, Arminja N Kettenbach, Roland L Dunbrack, Xavier Graña
FAM122A ensures cell cycle interphase progression and checkpoint control by inhibiting B55α/PP2A through helical motifs. Nature communications 15 (1) (2024)
Jason S Wasserman, Bulat Faezov, Kishan R Patel, Alison N Kurimchak, Seren M Palacio, David J Glass, Holly Fowle, Brennan C McEwan, Qifang Xu, Ziran Zhao, Lauren E Cressey, Neil Johnson, James S Duncan, Arminja N Kettenbach, Roland L Dunbrack, Xavier Graña
FAM122A ensures cell cycle interphase progression and checkpoint control by inhibiting B55α/PP2A through helical motifs. Nature communications 15 (1) (2024)
Konstantin Budyagan, Alexa C Cannon, Adam Chatoff, Nathaniel W Snyder, Alison N Kurimchak, James S Duncan, Jonathan Chernoff
KRAS mutation-selective requirement for ACSS2 in colorectal adenoma formation. Research square (2024)
Alexa C Cannon, Konstantin Budagyan, Cristina Uribe-Alvarez, Alison N Kurimchak, Daniela Araiza-Olivera, Kathy Q Cai, Suraj Peri, Yan Zhou, James S Duncan, Jonathan Chernoff
Unique vulnerability of RAC1-mutant melanoma to combined inhibition of CDK9 and immune checkpoints. Oncogene 43 (10) (2024)
Alexa C Cannon, Konstantin Budagyan, Cristina Uribe-Alvarez, Alison N Kurimchak, Daniela Araiza-Olivera, Kathy Q Cai, Suraj Peri, Yan Zhou, James S Duncan, Jonathan Chernoff
Unique vulnerability of RAC1-mutant melanoma to combined inhibition of CDK9 and immune checkpoints. Oncogene 43 (10) (2024)
Jason S Wasserman, Bulat Faezov, Kishan R Patel, Alison N Kurimchak, Seren M Palacio, Holly Fowle, Brennan C McEwan, Qifang Xu, Ziran Zhao, Lauren Cressey, Neil Johnson, James S Duncan, Arminja N Kettenbach, Roland L Dunbrack, Xavier Graña
FAM122A ensures cell cycle interphase progression and checkpoint control as a SLiM-dependent substrate-competitive inhibitor to the B55⍺/PP2A phosphatase. bioRxiv : the preprint server for biology (2023)
Alison N Kurimchak, Carlos Herrera-Montávez, Sara Montserrat-Sangrà, Daniela Araiza-Olivera, Jianping Hu, Ryan Neumann-Domer, Mathew Kuruvilla, Alfonso Bellacosa, Joseph R Testa, Jian Jin, James S Duncan
The drug efflux pump MDR1 promotes intrinsic and acquired resistance to PROTACs in cancer cells. Science signaling 15 (749) (2022)
Alison N Kurimchak, Carlos Herrera-Montávez, Jennifer Brown, Katherine J Johnson, Valerie Sodi, Nishi Srivastava, Vikas Kumar, Safoora Deihimi, Shane O'Brien, Suraj Peri, Gina M Mantia-Smaldone, Angela Jain, Ryan M Winters, Kathy Q Cai, Jonathan Chernoff, Denise C Connolly, James S Duncan
Functional proteomics interrogation of the kinome identifies MRCKA as a therapeutic target in high-grade serous ovarian carcinoma. Science signaling 13 (619) (2020)